Mitiglinide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mitiglinide
Mitiglinide.svg
Clinical data
Trade names Glufast
AHFS/Drugs.com International Drug Names
Routes of
administration
By mouth (tablets)
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C19H25NO3
Molar mass 315.41 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology[edit]

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

Dosage[edit]

Mitiglinide is delivered in tablet form.

References[edit]

External links[edit]